Pacira Pharmaceuticals Statement on FDA Advisory Committee for EXPAREL® for Use as a Nerve Block to Produce Regional Analgesia
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Needham & Company Downgrades Pacira Pharmaceuticals (PCRX) to Hold
February 16, 2018 7:20 AM ESTNeedham & Company downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Buy to Hold.
Analyst Serge Belanger commented, "The FDA's briefing documents presaged a difficult AdCom panel review for Exparel's potential label expansion to nerve blocks. Over the 2-day panel, panel members echoed the FDA's concerns... More
Pacira Pharmaceuticals (PCRX) PT Lowered to $32 at BMO Capital
February 16, 2018 6:11 AM ESTBMO Capital lowered its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $32.00 (from $41.00) while maintaining a Market Perform rating.
Analyst Gary Nachman commented, "FDA panel voted against approving the nerve block (NB) indication for Exparel (6 No, 4 Yes). We anticipated a complicated... More
Pacira Pharma (PCRX) to Resume Trading at 4:15 pm ET
February 15, 2018 3:51 PM ESTPacira Pharma (NASDAQ: PCRX) to Resume Trading at 4:15 pm ET
... MorePacira Pharma (PCRX) Confirms Only Four FDA Committee Members Voted to Recommend Approval of EXPAREL sNDA
February 15, 2018 3:36 PM ESTPacira Pharmaceuticals, Inc. (NASDAQ: PCRX), announced today that the U.S. Food and Drug Administrations (FDA) Anesthetic and Analgesic Drug Products Advisory Committee did not reach a unanimous decision on the efficacy and safety of the use of EXPAREL® (bupivacaine liposome injectable suspension) as a nerve block to produce regional analgesia. The committees feedback will be considered by the FDA in its review of the companys sNDA seeking expansion of the... More
